The Pharmaceutical Benefits Advisory Committee (PBAC) will become gatekeeper in the government’s new push to increase the uptake of biosimilars. From July 1, two new policies outlined in the latest five-year agreement between the federal government and Medicines Australia will empower the PBAC to recommend differential prescribing rules for biosimilars and reference biologics. There are currently three ...
Policies to drive biosimilar uptake may have ‘unintended consequences’, experts warn
By Tessa Hoffman
7 Jun 2017